MedTrace Logo

Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer

NCT05767931 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-03-14

No results posted yet for this study

Summary

This is a prospective, single-center, non-randomized, non-controlled study

Conditions

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Zhaoqing Fan · Breast center at Peking University Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2024-11-06
Completion
2025-03-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05767931 on ClinicalTrials.gov